drugset
drugset / Trial / NCT02685462

Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin

NCT02685462 ↗

Phase 1 Completed 36 enrolled Tobira Therapeutics, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase 1, Open-Label, 3-Period, Single-sequence, Drug-drug Interaction Study in Healthy Subjects to Assess the Effect of Cenicriviroc on the Pharmacokinetics (PK) of HMG-CoA Reductase Inhibitors \[Rosuvastatin (ROS), Atorvastatin (ATO) and Simvastatin (SIM)\], Caffeine and Digoxin

Timeline

Start
2016-01-31
Primary completion
2016-02-23
Completion
2016-02-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 20 mg —
Subject Caffeine Small molecule 200 mg —
Subject Digoxin Other / unclassified 0.25 mg —
Subject Rosuvastatin Small molecule 20 mg —
Subject Simvastatin Small molecule 20 mg —

Indications

No indication recorded.